Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity
14:40 EDT 2 Aug 2012 | Elsevier Business Intelligence
Bristol had paid $2.5 billion to buy Inhibitex and its Phase II nucleoside polymerase inhibitor in hopes of keeping pace with Gilead in the race to develop the first all-oral combination of direct-acting antivirals for hepatitis C.
Original Article: Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity
More From BioPortfolio on "Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
